To Get More Information on Vaccines Market - Request Sample Report
The Vaccine Market Size was valued at USD 74.7 billion in 2023 and is expected to reach USD 186.5 billion by 2032 and grow at a CAGR of 10.7% during the forecasted period 2024-2032.
The vaccine market plays a crucial role in global public health through preventing infectious diseases and protecting communities. In this contemporary world, vaccination is one of the most effective public health strategies through various vaccines that are recommended, sometimes mandatorily by different regions. From birth, most children are vaccinated with essential vaccines including those for hepatitis B, diphtheria, tetanus, pertussis sometimes called whooping cough, polio, Haemophilus influenzae type b (Hib), pneumococcal disease, measles, mumps, and rubella (MMR). These vaccines prevent the deadliest diseases and form the backbone of national immunization programs in countries like the United States, Canada, Australia, and most of Europe.
As children grow up, they need more immunization against diseases that can cause lifelong consequences. For instance, the HPV vaccine is an important aspect of preventing sexually transmitted infections while the meningococcal vaccine protects against bacterial meningitis. Adults are not excluded either; Td booster shots and the annual flu vaccine are often required in many regions as a way of maintaining their immunity against prevalent and contagious diseases.
Vaccines are increasingly recommended in older populations, particularly senior citizens, to cut the risks associated with infections that are particularly dangerous in such persons. The list of vaccines considered necessary is subject to varying degrees of difference across countries and regions according to public health policy, the prevalence of diseases, and the availability of healthcare resources.
In recent times, the market for vaccines has grown by leaps and bounds due to heightened awareness among many about the importance of vaccination, pro-active efforts from the government, and the pace of advancement in vaccine technology. Within this very context, health crises at global levels, such as the COVID-19 pandemic, have created a tremendous imperative for strong vaccination programs at both global and local levels that will speed up investment and innovation in the vaccine industry. This increased pace of vaccine research and development created new vaccine technologies most notably effective of which were the mRNA vaccines, especially for the control of emerging infectious diseases.
The collaborations are further strengthening the vaccine distribution capabilities. By March 2024, Dr. Reddy's Laboratories (DRL) would market and distribute Sanofi's vaccine brands in India. The agreement pertains to the group's best-selling vaccines for pediatrics and adults: Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel, and Avaxim 80U, which sold USD 51 million combined through February 2024. In this business venture, DRL will hold a share of vaccine sales in India, while Sanofi maintains rights to its ownership and manufacturing.
| Country | Compulsory Vaccines | Recommended Vaccines |
|
USA |
Hepatitis B, Rotavirus, DTaP, Hib, PCV13, IPV, Influenza, MMR, Varicella, Hepatitis A, Meningococcal |
HPV, Meningococcal B, Dengue (in endemic areas) |
|
Germany |
Measles |
Diphtheria, Tetanus, Whooping Cough, Polio, Hib, Hepatitis B, Meningococcus B and C, Pneumococci, MMR, Chickenpox, HPV, Rotavirus |
|
France |
DTP (Diphtheria, Tetanus, Polio), Pertussis, Hib, Hepatitis B, Pneumococcal, Meningococcal C, MMR, Yellow Fever (in Guyana) |
Tuberculosis (high-risk), Meningococci B, Chickenpox, Influenza, Shingles, HPV, Rotavirus |
|
Italy |
Diphtheria, Tetanus, Polio, Hepatitis B, Pertussis, Haemophilus influenzae type B, Meningococcal B and C, Measles, Mumps, Rubella, Chickenpox |
Pneumococcal, Rotavirus, HPV (12th year), Meningococcal ACWY |
|
China |
Hepatitis B, Polio, DTaP, Japanese Encephalitis, MMR |
Influenza, Pneumococcal vaccines |
|
India |
BCG, Hepatitis B, Polio (OPV & IPV), Rotavirus, Measles, DTP, Hib, Pneumococcal |
Typhoid, Hepatitis A, Chickenpox, MMR (second dose), Influenza |
|
South Africa |
BCG, Hepatitis B, Polio (OPV & IPV), Rotavirus, Measles, DTP, Hib, Pneumococcal, HPV (females only) |
Influenza, Meningococcal vaccines, Measles (second dose) |
Drivers
Government Support, Innovation, and Supply Dynamics
Strong product supply and adequate investments in research and development (R&D) are the prime growth drivers for the global vaccine market. Overall, the immunity programs undertaken by governments around the globe to eradicate endemic diseases are ensuring that there is considerable demand for a constant supply of vaccines. Hospitals, government foundations, and pharmaceutical companies play a very important role as they ensure a steady supply of vaccines for these immunization campaigns. The ready availability of low-cost immunization, combined with government surveillance, allows vaccination programs to be readily available to broad sections of populations, often at minimal or no cost.
For instance, the WHO has allocated about 18 million doses of the malaria vaccine to 12 African countries under the Malaria Vaccine Implementation Programme (MVIP) for the period 2023–2025. Other factors driving market growth include ongoing demand for vaccines against diseases like diphtheria, tetanus, pertussis, and malaria. Apart from this, funding by government agencies and corporate investments in vaccine research has accelerated the introduction of new products.
Pharmaceutical companies, with a good vaccine candidate at hand and a strong innovation pipeline, are scouting ways to build momentum. Other significant players that would define the future of this market include Inovio Pharmaceuticals, Novavax, and Bavarian Nordic. Major players such as Pfizer, GSK, Sanofi, and Merck would also be in a position to drive growth through their research and development efforts. For instance, Pfizer has in its pipeline Lyme disease and Clostridioides difficile infection vaccines, phase 3 candidates that already show huge market potential for more progress. Another example is an mRNA-based influenza vaccine under phase 3 trials.
Restraints
High Vaccine Cost A Key Challenge to High Growth Rates
By Type
The mRNA segment captured a market share of 32.3% in 2023 and thus, leads the vaccine market. Pfizer/BioNTech and Moderna have emerged as two of the most prominent players with their mRNA-based COVID-19 vaccines. Rapid modification of antigen design and incorporation of sequences of multiple variants to respond to newly developed viral mutations are some of the advantages of mRNA-based vaccines over traditional vaccines. This is one of the major factors behind its leadership in the market.
During the forecast period, the subunit vaccines segment is expected to experience strong growth. This is attributed to the prevalent prevalence of infectious diseases and increasing demand for superior and safer vaccines, along with an intense focus on preventive healthcare. There is also a great surge for more effective vaccines targeted to diseases such as cancer, autoimmune diseases, and allergies.
By Route of Administration
Parenteral administration dominated the vaccine delivery method with a 97.0% market capture in 2023. This injective method offers immediate absorption, higher efficacy, and lower chances of contamination or degradation compared to other forms of vaccine administration. Most vaccines distributed in the market are intramuscularly or subcutaneously injected.
The oral Administration segment will witness steady growth in the forecast period. The growth is due to the advantages that oral vaccines bring forth, including stimulation of both mucosal and systemic immunity and without side effects commonly associated with injections. Oral vaccines, for instance, polio and rotavirus vaccines, commonly administered in pediatric immunization, are major drivers for that expansion.
By Indication
The viral diseases vaccine segment, which includes vaccines for Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, COVID-19, and others, held the largest share at 63.7% in the market in 2023, primarily due to COVID-19 vaccines. These are driven by the high prevalence of viral infections, increasing awareness of the benefits of vaccinations, and government-supported immunization programs. The market is highly competitive and is dominated by major companies such as Pfizer, GSK, AstraZeneca, and the Serum Institute.
The bacterial diseases segment is predicted to have growth at the highest CAGR during the forecast period. This is due to the increasing demand for vaccines that offer protection against bacterial infections, especially in regions wherein the prevalence of bacterial diseases is highly severe. The segment includes vaccines for bacterial infections like pneumonia, meningitis, DPT, and more.
By Age
In 2023, the adult segment contributed to 57.2% of the vaccine market, as adult vaccinations—mostly COVID-19—represent 75% of the global volume. In contrast, pediatric vaccines account for around 20%. Adult vaccine volumes grew nine-fold compared to pre-COVID levels as a result of mainly COVID-19 vaccinations. Non-COVID-19 adult vaccine volumes also surged 15%, largely due to the increased use of seasonal influenza vaccines in HICs.
The pediatric vaccine segment is expected to grow at the highest rate during the forecast period. Volumes of pediatric vaccine sales are currently at 14% lower than pre-pandemic levels, due to lessened uptake of oral polio and measles-rubella vaccines during SIAs implemented during the COVID-19 pandemic.
By Distribution Channel
Government suppliers dominate the 2023 vaccine market with a share of 59.90%. Vaccines rely much more than other pharmaceutical products on public funding by way of government and pooled procurement arrangements, rather than private sources. Most pharmaceutical products are therefore different from vaccines in that centralizing demand facilitates supply planning but predictability remains highly critical for the delivery of access to vaccines.
The hospital and retail pharmacy supply channel is expected to be the fastest growing among the vaccine market's different distribution channels. Pharmacies, particularly in developed countries, are increasingly assuming vital source positions for vaccination among the public by promoting easier access and increased rates of vaccination. The private market for COVID-19 vaccines is supposed to open in the United States in 2023, creating a driver for growth in this market also.
The North American market is expected to grow at a high compound annual growth rate of 8.42% during the forecast period, majorly owing to government-led immunization initiatives and increased public awareness after the breakout of COVID-19. Along with the growing demand for more effective vaccines, in the U.S., updated Hepatitis B vaccination guidelines from the CDC are actively being supported by organizations like the Hepatitis B Foundation for enhanced coverage among U.S. adults, while about 2.4 million Americans suffer from chronic hepatitis B and thousands die yearly. Moreover, advances in vaccine technology are coupled with recent U.S. FDA approvals that can drive the market growth forward.
In Europe, in 2023, the vaccine market occupied the second position globally, primarily as a result of better funding for research and the growing number of biopharmaceutical companies. The UK is one of the strongest participants in the region, with positive trends in terms of vaccine uptake, strong immunization programs, and gigantic government investment in vaccine development. In 2022, the UK allocated USD 192 million to the Coalition for Epidemic Preparedness Innovations for global vaccine development. Additionally, Pfizer received a positive opinion last week from the European Medicines Agency's Committee for Medicinal Products for Human Use for its 20-Valent Pneumococcal Conjugate Vaccine providing broad protection against pneumococcal disease for January 2024.
The Asia Pacific vaccines market held the biggest share of 30.86% in 2023 and was expected to grow at the highest rate during the forecast period. This growth is fueled by improving healthcare reforms, a rising elderly population, and increasing investments in healthcare infrastructure. Key countries that contribute to this growth include India and China, which arise due to the growing presence of influenza and government initiatives to expand next-generation vaccines. Japan's technologically advanced market is also growing rapidly due to government grants and initiatives for reducing the flu burden. In September 2023, Pfizer Japan sought approval for its 20-valent pneumococcal conjugate vaccine, Apexxnar, directed at adults over 65 and those who would be at risk for pneumococcal infections. This new vaccine was designed to offer broader protection than previous vaccines, covering more serotypes.
Do You Need any Customization Research on Vaccines Market - Enquire Now
GSK Plc.
Merck & Co., Inc.
Pfizer Inc.
Moderna Inc.
Sinovac
BioNTech SE
AstraZeneca
Novartis AG
Emergent BioSolutions, Inc.
Inovio Pharmaceuticals, Inc.
Bavarian Nordic
Mitsubishi Tanabe Pharma Corporation
Bavarian Nordic
CSL Limited, and others.
In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to jointly commercialize a COVID-19 vaccine and collaborate on the development of innovative combination vaccines targeting both COVID-19 and influenza. This strategic alliance allows both companies to harness their strengths and resources, aiming to accelerate the delivery of cutting-edge vaccine solutions to the market. Through this partnership, Novavax and Sanofi seek to strengthen their competitive edge in the rapidly evolving vaccine industry, while proactively addressing public health challenges and meeting the growing global demand for effective vaccines against infectious diseases.
In April 2023, Pfizer revealed promising data from phase 3 trials of its RSV vaccine. The trials, conducted among adult participants, showed that the vaccine was 67% effective in preventing infections with two associated symptoms and 86% effective in severe cases. Upon approval, this vaccine would become the first product available in the RSV market.
| Report Attributes | Details |
| Market Size in 2023 | US$ 74.7 Billion |
| Market Size by 2032 | US$ 186.5 Billion |
| CAGR | CAGR of 10.7% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Subunit Vaccines, Inactivated, Live attenuated, mRNA vaccines, Viral vector vaccines) • By Route of Administration (Oral, Parenteral, Nasal) • By Indication (Viral Diseases, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines) • By Age (Pediatric, Adult) • By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Serum Institute of India Pvt. Ltd., Seqirus, Sanofi, GSK Plc., Merck & Co., Inc., Pfizer Inc., Moderna Inc., Sinovac, BioNTech SE, AstraZeneca, Novartis AG and Other Players |
| Key Drivers | • Government Support, Innovation, and Supply Dynamics |
| Market Restraints | • High Vaccine Cost A Key Challenge to High Growth Rates |
Ans : The Vaccines Market was valued at USD 74.7 billion in 2023 and is expected to reach USD 186.5 billion by 2032 and grow at a CAGR of 10.7% during the forecasted period 2023-2030.
Ans: The rising diseases, clinical trials where the need of vaccines is upheld.
Ans : The major key players are Sanofi, Pfizer, GlaxoSmithKline plc, Merck & Co, Inc, Inovio pharmaceuticals, Inc, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Moderna and others.
Ans : During a recession, governments and healthcare budgets may experience difficulties, which could result in decreased funding for healthcare efforts like vaccination campaigns.
Ans: Vaccines market is divided into four segments.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Vaccine Market Segmentation, by Type
7.1 Chapter Overview
7.2 Subunit Vaccines
7.2.1 Subunit Vaccines Market Trends Analysis (2020-2032)
7.2.2 Subunit Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Inactivated
7.3.1 Inactivated Market Trends Analysis (2020-2032)
7.3.2 Inactivated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Live attenuated
7.4.1 Live attenuated Market Trends Analysis (2020-2032)
7.4.2 Live attenuated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 mRNA vaccines
7.5.1 mRNA Vaccines Market Trends Analysis (2020-2032)
7.5.2 mRNA Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Viral vector vaccines
7.6.1 Viral vector vaccines Market Trends Analysis (2020-2032)
7.6.2 Viral Vector Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Vaccine Market Segmentation, By Route of Administration
8.1 Chapter Overview
8.2 Oral
8.2.1 Oral Market Trends Analysis (2020-2032)
8.2.2 Oral Market Size Estimates And Forecasts To 2032 (USD Billion)
8.3 Parenteral
8.3.1 Parenteral Market Trends Analysis (2020-2032)
8.3.2 Parenteral Market Size Estimates And Forecasts To 2032 (USD Billion)
8.4 Nasal
8.4.1 Nasal Market Trends Analysis (2020-2032)
8.4.2 Nasal Market Size Estimates And Forecasts To 2032 (USD Billion)
9. Vaccine Market Segmentation, By Indication
9.1 Chapter Overview
9.2 Viral Diseases
9.2.1 Viral Diseases Market Trends Analysis (2020-2032)
9.2.2 Viral Diseases Market Size Estimates And Forecasts To 2032 (USD Billion)
9.3 Bacterial Vaccines
9.3.1 Bacterial Vaccines Market Trends Analysis (2020-2032)
9.3.2 Bacterial Vaccines Market Size Estimates And Forecasts To 2032 (USD Billion)
9.4 Cancer Vaccines
9.4.1 Cancer Vaccines Market Trends Analysis (2020-2032)
9.4.2 Cancer Vaccines Market Size Estimates And Forecasts To 2032 (USD Billion)
9.5 Allergy Vaccines
9.5.1 Allergy Vaccines Market Trends Analysis (2020-2032)
9.5.2 Allergy Vaccines Market Size Estimates And Forecasts To 2032 (USD Billion)
10. Vaccine Market Segmentation, By Age
10.1 Chapter Overview
10.2 Pediatric
10.2.1 Pediatric Market Trends Analysis (2020-2032)
10.2.2 Pediatric Market Size Estimates And Forecasts To 2032 (USD Billion)
10.3 Adult
10.3.1 Adult Market Trends Analysis (2020-2032)
10.3.2 Adult Market Size Estimates And Forecasts To 2032 (USD Billion)
11. Vaccine Market Segmentation, By Distribution Channel
11.1 Chapter Overview
11.2 Hospital & Retail Pharmacies
11.2.1 Hospital & Retail Pharmacies Market Trends Analysis (2020-2032)
11.2.2 Hospital & Retail Pharmacies Market Size Estimates And Forecasts To 2032 (USD Billion)
11.3 Government Suppliers
11.3.1 Government Suppliers Market Trends Analysis (2020-2032)
11.3.2 Government Suppliers Market Size Estimates And Forecasts To 2032 (USD Billion)
11.4 Others
11.4.1 Others Market Trends Analysis (2020-2032)
11.4.2 Others Market Size Estimates And Forecasts To 2032 (USD Billion)
12. Regional Analysis
12.1 Chapter Overview
12.2 North America
12.2.1 Trends Analysis
12.2.2 North America Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.2.3 North America Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.2.4 North America Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.2.5 North America Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.2.6 North America Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.2.7 North America Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.2.8 USA
12.2.8.1 USA Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.2.8.2 USA Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.2.8.3 USA Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.2.8.4 USA Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.2.8.5 USA Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.2.9 Canada
12.2.9.1 Canada Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.2.9.2 Canada Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.2.9.3 Canada Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.2.9.4 Canada Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.2.9.5 Canada Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.2.10 Mexico
12.2.10.1 Mexico Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.2.10.2 Mexico Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.2.10.3 Mexico Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.2.10.4 Mexico Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.2.10.5 Mexico Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Trends Analysis
12.3.1.2 Eastern Europe Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.3.1.3 Eastern Europe Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.4 Eastern Europe Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.5 Eastern Europe Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.6 Eastern Europe Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.7 Eastern Europe Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.1.8 Poland
12.3.1.8.1 Poland Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.8.2 Poland Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.8.3 Poland Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.8.4 Poland Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.8.5 Poland Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.1.9 Romania
12.3.1.9.1 Romania Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.9.2 Romania Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.9.3 Romania Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.9.4 Romania Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.9.5 Romania Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.1.10 Hungary
12.3.1.10.1 Hungary Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.10.2 Hungary Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.10.3 Hungary Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.10.4 Hungary Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.10.5 Hungary Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.1.11 Turkey
12.3.1.11.1 Turkey Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.11.2 Turkey Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.11.3 Turkey Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.11.4 Turkey Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.11.5 Turkey Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.1.12 Rest Of Eastern Europe
12.3.1.12.1 Rest Of Eastern Europe Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.1.12.2 Rest Of Eastern Europe Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.1.12.3 Rest Of Eastern Europe Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.1.12.4 Rest Of Eastern Europe Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.1.12.5 Rest Of Eastern Europe Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2 Western Europe
12.3.2.1 Trends Analysis
12.3.2.2 Western Europe Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.3.2.3 Western Europe Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.4 Western Europe Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.5 Western Europe Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.6 Western Europe Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.7 Western Europe Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.8 Germany
12.3.2.8.1 Germany Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.8.2 Germany Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.8.3 Germany Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.8.4 Germany Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.8.5 Germany Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.9 France
12.3.2.9.1 France Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.9.2 France Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.9.3 France Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.9.4 France Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.9.5 France Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.10 UK
12.3.2.10.1 UK Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.10.2 UK Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.10.3 UK Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.10.4 UK Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.10.5 UK Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.11 Italy
12.3.2.11.1 Italy Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.11.2 Italy Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.11.3 Italy Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.11.4 Italy Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.11.5 Italy Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.12 Spain
12.3.2.12.1 Spain Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.12.2 Spain Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.12.3 Spain Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.12.4 Spain Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.12.5 Spain Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.13 Netherlands
12.3.2.13.1 Netherlands Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.13.2 Netherlands Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.13.3 Netherlands Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.13.4 Netherlands Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.13.5 Netherlands Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.14 Switzerland
12.3.2.14.1 Switzerland Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.14.2 Switzerland Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.14.3 Switzerland Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.14.4 Switzerland Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.12.5 Switzerland Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.15 Austria
12.3.2.15.1 Austria Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.15.2 Austria Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.15.3 Austria Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.15.4 Austria Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.15.5 Austria Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.3.2.16 Rest Of Western Europe
12.3.2.16.1 Rest Of Western Europe Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.3.2.16.2 Rest Of Western Europe Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.3.2.16.3 Rest Of Western Europe Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.3.2.16.4 Rest Of Western Europe Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.3.2.16.5 Rest Of Western Europe Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4 Asia Pacific
12.4.1 Trends Analysis
12.4.2 Asia Pacific Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.4.3 Asia Pacific Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.4 Asia Pacific Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.5 Asia Pacific Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.6 Asia Pacific Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.7 Asia Pacific Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.8 China
12.4.8.1 China Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.8.2 China Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.8.3 China Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.8.4 China Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.8.5 China Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.9 India
12.4.9.1 India Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.9.2 India Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.9.3 India Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.9.4 India Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.9.5 India Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.10 Japan
12.4.10.1 Japan Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.10.2 Japan Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.10.3 Japan Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.10.4 Japan Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.10.5 Japan Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.11 South Korea
12.4.11.1 South Korea Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.11.2 South Korea Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.11.3 South Korea Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.11.4 South Korea Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.11.5 South Korea Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.12 Vietnam
12.4.12.1 Vietnam Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.12.2 Vietnam Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.12.3 Vietnam Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.12.4 Vietnam Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.12.5 Vietnam Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.13 Singapore
12.4.13.1 Singapore Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.13.2 Singapore Vaccine Market Estimates And Forecasts, By Route of Administration(2020-2032) (USD Billion)
12.4.13.3 Singapore Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.13.4 Singapore Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.13.5 Singapore Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.14 Australia
12.4.14.1 Australia Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.14.2 Australia Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.14.3 Australia Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.14.4 Australia Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.14.5 Australia Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.4.15 Rest Of Asia Pacific
12.4.15.1 Rest Of Asia Pacific Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.4.15.2 Rest Of Asia Pacific Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.4.15.3 Rest Of Asia Pacific Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.4.15.4 Rest Of Asia Pacific Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.4.15.5 Rest Of Asia Pacific Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5 Middle East And Africa
12.5.1 Middle East
12.5.1.1 Trends Analysis
12.5.1.2 Middle East Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.5.1.3 Middle East Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.4 Middle East Vaccine Market Estimates And Forecasts, By Application (2020-2032) (USD Billion)
12.5.1.5 Middle East Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.6 Middle East Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.7 Middle East Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.1.8 UAE
12.5.1.8.1 UAE Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.8.2 UAE Vaccine Market Estimates And Forecasts, By Application (2020-2032) (USD Billion)
12.5.1.8.3 UAE Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.8.4 UAE Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.8.5 UAE Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.1.9 Egypt
12.5.1.9.1 Egypt Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.9.2 Egypt Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.1.9.3 Egypt Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.9.4 Egypt Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.9.5 Egypt Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.1.10 Saudi Arabia
12.5.1.10.1 Saudi Arabia Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.10.2 Saudi Arabia Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.1.10.3 Saudi Arabia Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.10.4 Saudi Arabia Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.10.5 Saudi Arabia Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.1.11 Qatar
12.5.1.11.1 Qatar Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.11.2 Qatar Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.1.11.3 Qatar Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.11.4 Qatar Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.11.5 Qatar Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.1.12 Rest Of Middle East
12.5.1.12.1 Rest Of Middle East Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.1.12.2 Rest Of Middle East Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.1.12.3 Rest Of Middle East Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.1.12.4 Rest Of Middle East Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.1.12.5 Rest Of Middle East Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.2 Africa
12.5.2.1 Trends Analysis
12.5.2.2 Africa Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.5.2.3 Africa Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.2.4 Africa Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.2.5 Africa Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.2.6 Africa Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.2.7 Africa Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.2.8 South Africa
12.5.2.8.1 South Africa Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.2.8.2 South Africa Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.2.8.3 South Africa Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.2.8.4 South Africa Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.2.8.5 South Africa Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.2.9 Nigeria
12.5.2.9.1 Nigeria Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.2.9.2 Nigeria Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.2.9.3 Nigeria Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.2.9.4 Nigeria Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.2.9.5 Nigeria Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.5.2.10 Rest Of Africa
12.5.2.10.1 Rest Of Africa Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.5.2.10.2 Rest Of Africa Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.5.2.10.3 Rest Of Africa Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.5.2.10.4 Rest Of Africa Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.5.2.10.5 Rest Of Africa Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.6 Latin America
12.6.1 Trends Analysis
12.6.2 Latin America Vaccine Market Estimates And Forecasts, By Country (2020-2032) (USD Billion)
12.6.3 Latin America Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.6.4 Latin America Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.6.5 Latin America Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.6.6 Latin America Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.6.7 Latin America Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.6.8 Brazil
12.6.8.1 Brazil Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.6.8.2 Brazil Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.6.8.3 Brazil Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.6.8.4 Brazil Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.6.8.5 Brazil Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.6.9 Argentina
12.6.9.1 Argentina Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.6.9.2 Argentina Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.6.9.3 Argentina Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.6.9.4 Argentina Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.6.9.5 Argentina Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.6.10 Colombia
12.6.10.1 Colombia Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.6.10.2 Colombia Vaccine Market Estimates And Forecasts, By Route of Administration (2020-2032) (USD Billion)
12.6.10.3 Colombia Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.6.10.4 Colombia Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.6.10.5 Colombia Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
12.6.11 Rest Of Latin America
12.6.11.1 Rest Of Latin America Vaccine Market Estimates And Forecasts, By Type (2020-2032) (USD Billion)
12.6.11.2 Rest Of Latin America Vaccine Market Estimates And Forecasts, By Application (2020-2032) (USD Billion)
12.6.11.3 Rest Of Latin America Vaccine Market Estimates And Forecasts, By Indication (2020-2032) (USD Billion)
12.6.11.4 Rest Of Latin America Vaccine Market Estimates And Forecasts, By Age (2020-2032) (USD Billion)
12.6.11.5 Rest Of Latin America Vaccine Market Estimates And Forecasts, By Distribution Channel (2020-2032) (USD Billion)
13. Company Profiles
13.1 Serum Institute of India Pvt. Ltd.
13.1.1 Company Overview
13.1.2 Financial
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.2 Seqirus
13.2.1 Company Overview
13.2.2 Financial
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.3 Sanofi
13.3.1 Company Overview
13.3.2 Financial
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.4 GSK Plc.
13.4.1 Company Overview
13.4.2 Financial
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.5 Pfizer Inc.
13.5.1 Company Overview
13.5.2 Financial
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.6 Moderna Inc.
13.6.1 Company Overview
13.6.2 Financial
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.7 AstraZeneca
13.7.1 Company Overview
13.7.2 Financial
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.8 Merck & Co., Inc.
13.8.1 Company Overview
13.8.2 Financial
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.10 Emergent BioSolutions, Inc.
13.12.1 Company Overview
13.12.2 Financial
13.12.3 Products/ Services Offered
13.12.4 SWOT Analysis
14. Use Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
Subunit Vaccines
Inactivated
Live attenuated
mRNA vaccines
Viral vector vaccines
By Route of Administration
Oral
Parenteral
Nasal
By Indication
Viral Diseases
Bacterial Vaccines
Cancer Vaccines
Allergy Vaccines
By Age
Pediatric
Adult
By Distribution Channel
Hospital & Retail Pharmacies
Government Suppliers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Heating Pad Market size was valued at USD 49920.16 Million in 2022 and is expected to grow to USD 75400.29 Million by 2030 and grow at a CAGR of 5.29% over the forecast period of 2023-2030.
The Hemophilia Market size was valued at USD 13.6 billion in 2023 and is expected to reach USD 22.50 billion by 2031 and grow at a CAGR of 6.5 % over the forecast period of 2024-2031.
The ultrasound equipment market size was valued at USD 9.47 billion in 2023, and is expected to reach USD 15.22 billion by 2032, and grow at a CAGR of 5.43% over the forecast period 2024-2032.
The Nasal Drug Delivery Market was estimated at USD 76.85 billion in 2023 and is poised to reach 137.06 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 7.5% for the forecast period of 2024-2031.
The Wound Care Market Size was valued at USD 22.3 billion in 2023, and is expected to reach USD 30.75 billion by 2031, and grow at a CAGR of 4.10% over the forecast period 2024-2031
The Radiopharmaceutical Injectors Market was valued at USD 27.8 million in 2023 and will reach USD 52.3 million by 2032, with a growing CAGR of 7.2% during the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
